Precision Hepatology in Clinical Practice


  • Saturday, November 9, 8:00 am – 5:00 pm

Program Chairs

  • Jorge A. Bezerra, MD, FAASLD
  • Andrew P. Keaveny, MD, FRCPI, FAASLD
  • Rebecca G. Wells, MD

Session Description / Needs Statement

Hepatology practice is undergoing major changes fueled by the discovery of disease biomarkers and digital strategies to stage and monitor clinical courses. Once glimpses of a possible future, minimally invasive tests and electronic resources are increasingly available in the clinic. In this Postgraduate Course, experts review how these advances improve care protocols and allow for precise, even customized clinical approaches.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Review evidence-based evaluation and management options available for a spectrum of liver diseases, their benefits and risks, and strategies to tailor treatment plans to individual patients
  • Discuss the value of circulating and tissue biomarkers in making rational decisions for optimal patient care
  • Apply information on minimally invasive tests and digital tools to identify biomarkers to the clinical practice of hepatology

Continuing Education

  • CME – 7.0 AMA PRA Category 1 Credits™
  • CE – 6.5 Contact Hours
  • ABIM MOC – 7.0 Points
  • ABP MOC – 7.0 Points
  • Eligible for 3.5 pharmacology hours

To view full programming being offered at The Liver Meeting®, visit the 2019 Online Program.

  • Session I: Precision Medicine in 2019
  • Session II: Evolution of Disease and Reversing Fibrosis
  • Session III: Autoimmune Diseases and Cholestasis
  • Session IV: Hepatic Neoplasms
  • Session V: Questions, Controversies and Value of Care

Moderators: Meena B. Bansal and Ronald J. Sokol

  • 8:00 am – 8:05 am
    Welcome and Introductions
  • 8:05 am – 8:25 am
    The Spectrum of Precision Medicine
    Konstantinos N. Lazaridis
  • 8:25 am – 8:45 am
    Influence of the Microbiome on Liver Disease Phenotype and Outcome
    Bernd Schnabl
  • 8:45 am – 9:05 am
    Precision Medicine and Patients at Risk for Drug-induced Liver Injury*
    Robert J. Fontana
  • 9:05 am - 9:25 am
    Clinical Models and Risk Assessment: Acute-on-Chronic Liver Failure as a Paradigm
    Jennifer C. Lai